DrugDashboards

Gastrocrom

cromolyn sodium · CROMOLYN SODIUM 20 mg/mL · Liquid · Oral · Viatris Specialty LLC

NDC 00037-0678-96 · 12 POUCH in 1 CARTON / 8 AMPULE in 1 POUCH / 5 mL in 1 AMPULE · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $2.43 per mL over the past year. It is in shortage right now. Put together: this is a fragile supply — if anything else goes wrong, there is very little slack to absorb it.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.43per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$2.21per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$2.21per unitnegotiated price across 2 plans — before rebates · Jul 1, 2024
  • Federal ceiling (Big4)$845.72per package of 96X5MLMylan Specialty L.P. · Jan 1, 2026
  • Medicaid generic ceiling (FUL)$0.5577per MLweighted avg manufacturer price $0.3187 · Aug 1, 202623% of what pharmacies pay — a deeper discount than 95% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$2.21per unit
middle half $2.21$2.21 · 2 plans · Jul 1, 2024
Est. net of rebates
$1.33–$1.66
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00Sep 2024Sep 2026$2.43
18 price points · per ML · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$1,226.64
Reported to Texas DSHS · 2026 annual filing · Viatris Specialty LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$315,308
136 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

55High risk

Several kinds of pressure are visible at once — each line below is a condition that historically precedes supply trouble, and this market is stacking them.

  • 1 active manufacturer+30
  • in shortage now+25

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for cromolyn sodium (other) in the next 90 days

price up 25% YoY · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $3,588.01 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA020479
TE code
AA
Approval date
Feb 29, 1996
Patents / exclusivity
None on file

Shortage history

  • In shortage now Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)Nov 3, 2023
    month 35 — 3× the typical 12-month other shortage · model puts 49% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of cromolyn sodium (Liquid)

LabelerStrengthFirst seenLast seen
Viatris Specialty LLCCROMOLYN SODIUM 20 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Gastrocrom — NDC 00037-0678-96," retrieved September 3, 2026, https://drugdashboards.com/drug/00037067896.

Free to cite with attribution — see how the data is put together.